- Home
- OFS vs ANVS Comparison
OFS vs ANVS Comparison
Compare OFS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | ANVS |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.2M | 46.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OFS | ANVS |
|---|---|---|
| Price | $4.02 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 130.6K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 16.67% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $1.19 |
| 52 Week High | $9.31 | $5.50 |
Technical Indicators
Market Signals| Indicator | OFS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 37.46 |
| Support Level | $2.72 | $1.57 |
| Resistance Level | $4.44 | $2.99 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 92.20 | 18.65 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.